These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15921782)

  • 21. Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension.
    Rdzanek A; Filipiak KJ; Karpiński G; Grabowski M; Opolski G
    Int J Cardiol; 2006 Jun; 110(2):175-8. PubMed ID: 16198012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart.
    Russell FD; Molenaar P
    Cardiovasc Res; 2004 Sep; 63(4):673-81. PubMed ID: 15306223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural and functional assessment of small arteries in patients with chronic heart failure.
    Hillier C; Cowburn PJ; Morton JJ; Dargie HJ; Cleland JG; McMurray JJ; McGrath JC
    Clin Sci (Lond); 1999 Dec; 97(6):671-9. PubMed ID: 10585894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of urotensin II in patients on dialysis.
    Totsune K; Takahashi K; Arihara Z; Sone M; Satoh F; Ito S; Kimura Y; Sasano H; Murakami O
    Lancet; 2001 Sep; 358(9284):810-1. PubMed ID: 11564491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The differential extraction and immunoluminometric assay of Urotensin II and Urotensin-related peptide in heart failure.
    Jani PP; Narayan H; Ng LL
    Peptides; 2013 Feb; 40():72-6. PubMed ID: 23270674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure.
    Lim M; Honisett S; Sparkes CD; Komesaroff P; Kompa A; Krum H
    Circulation; 2004 Mar; 109(10):1212-4. PubMed ID: 15007012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urotensin II evokes potent vasoconstriction in humans in vivo.
    Böhm F; Pernow J
    Br J Pharmacol; 2002 Jan; 135(1):25-7. PubMed ID: 11786476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased circulating endothelins are not of cardiopulmonary origin in heart failure patients.
    Wang YZ; Goetze JP; Videbaek R; Rehfeld JF; Kastrup J
    Scand J Clin Lab Invest; 2005; 65(4):341-7. PubMed ID: 16076689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Venous endothelin receptor function in patients with chronic heart failure.
    Love MP; Haynes WG; Webb DJ; McMurray JJ
    Clin Sci (Lond); 2000 Jan; 98(1):65-70. PubMed ID: 10600660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urotensin-II levels in acute coronary syndromes.
    Joyal D; Huynh T; Aiyar N; Guida B; Douglas S; Giaid A
    Int J Cardiol; 2006 Mar; 108(1):31-5. PubMed ID: 16516696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Urotensin II].
    Takahashi K; Totsune K; Murakami O
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():603-5. PubMed ID: 16149588
    [No Abstract]   [Full Text] [Related]  

  • 32. Increased plasma urotensin II levels in patients with diabetes mellitus.
    Totsune K; Takahashi K; Arihara Z; Sone M; Ito S; Murakami O
    Clin Sci (Lond); 2003 Jan; 104(1):1-5. PubMed ID: 12519081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevation of plasmatic endothelin in patients with heart failure.
    Galindo-Fraga A; Arrieta O; Castillo-Martínez L; Narváez R; Oseguera-Moguel J; Orea-Tejeda A
    Arch Med Res; 2003; 34(5):367-72. PubMed ID: 14602502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension.
    Kemp W; Krum H; Colman J; Bailey M; Yandle T; Richards M; Roberts S
    Liver Int; 2007 Nov; 27(9):1232-9. PubMed ID: 17919235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Urotensin II--new peptide which regulates function of cardiovascular system].
    Jołda-Mydłowska B
    Pol Merkur Lekarski; 2004 May; 16(95):474-6. PubMed ID: 15518431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure.
    Nakayama T; Hirose T; Totsune K; Mori N; Maruyama Y; Maejima T; Minagawa K; Morimoto R; Asayama K; Kikuya M; Ohkubo T; Hashimoto J; Kohzuki M; Takahashi K; Imai Y
    Peptides; 2008 May; 29(5):801-8. PubMed ID: 18314225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries.
    Maguire JJ; Kuc RE; Wiley KE; Kleinz MJ; Davenport AP
    Peptides; 2004 Oct; 25(10):1767-74. PubMed ID: 15476944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.
    Douglas SA; Ohlstein EH
    Trends Cardiovasc Med; 2000 Aug; 10(6):229-37. PubMed ID: 11282300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Big endothelin and chronic heart failure].
    Spinar J; Spinarová L; Vítovec J; Ludka O; Hubená G; Tomandlová M; Tomandl J
    Vnitr Lek; 2002 Jan; 48(1):3-7. PubMed ID: 11852584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of urotensin II on skin microvessel tone in diabetic patients without heart failure or essential hypertension.
    Zomer E; de Ridder I; Kompa A; Komesaroff P; Gilbert R; Krum H
    Clin Exp Pharmacol Physiol; 2008 Oct; 35(10):1147-50. PubMed ID: 18505448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.